Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTGTXTG Therapeutics$37.08-1.6%$36.05$16.65▼$46.48$5.98B1.912.88 million shs957,478 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTGTXTG Therapeutics-0.66%+1.26%-4.46%+2.62%+83.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTGTXTG Therapeutics3.7965 of 5 stars2.40.00.03.53.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTGTXTG Therapeutics 2.80Moderate Buy$43.8018.12% UpsideCurrent Analyst Ratings BreakdownLatest TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTGTXTG Therapeutics$329M17.89$0.12 per share314.02$1.43 per share25.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTGTXTG Therapeutics$23.38M$0.24154.5037.08N/A10.13%18.88%7.05%8/5/2025 (Estimated)Latest TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025TGTXTG Therapeutics$0.27N/AN/AN/A$147.76 millionN/A5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTGTXTG Therapeutics1.034.023.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipTGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableTGTX HeadlinesRecent News About These CompaniesBanque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)July 11 at 5:39 AM | marketbeat.comTG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90July 10 at 10:31 PM | msn.comTG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite RatingJuly 10 at 10:31 PM | msn.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 10 at 11:09 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs GroupJuly 10 at 10:24 AM | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLCJuly 9 at 3:32 AM | marketbeat.comAxsome Therapeutics Sees Relative Strength Rating Climb To 79July 8 at 1:53 PM | msn.comPenserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8 at 5:57 AM | marketbeat.comPrincipal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8 at 4:13 AM | marketbeat.comNew York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 7, 2025 | marketbeat.comBraun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comJim Cramer on TG Therapeutics: “You Should Buy the Stock”July 2, 2025 | insidermonkey.comKymera Therapeutics Shows Market Leadership With Jump To 93 RS RatingJuly 2, 2025 | msn.comCramer's Lightning Round: TG Therapeutics is a buyJune 30, 2025 | nbcnewyork.comNTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement FundJune 30, 2025 | marketbeat.comTGTX - TG Therapeutics Inc Financials - MorningstarJune 28, 2025 | morningstar.comMTG Therapeutics: Strong Execution Tempered By An Evolving MarketJune 28, 2025 | seekingalpha.comSpire Wealth Management Acquires 22,750 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)June 28, 2025 | marketbeat.comTGTX - TG Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMStocks With Rising Relative Strength: CRISPR TherapeuticsJune 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTGTX Company DescriptionsTG Therapeutics NASDAQ:TGTX$37.08 -0.59 (-1.57%) Closing price 04:00 PM EasternExtended Trading$37.16 +0.08 (+0.22%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
